FILTER
FILTERED INTERVIEW RESULTS
Mohal K Sarabhai
CEO, ASENCE PHARMA PRIVATE LIMITED, (AMBALAL SARABHAI ENTERPRISES LTD (ASE) GROUP)
ASE is one of the oldest pharmaceutical companies in India and re-emerged as a parent company for different subsidiaries.
Ravi Jagtap
MANAGING DIRECTOR, AASTRID LIFE SCIENCES
Aastrid Life Sciences discusses how a focus on niche molecules and a commitment to quality assurance has made the company successful.
Rahul Nachane
MANAGING DIRECTOR, NGL FINE CHEM
NGL Fine Chem is a manufacturer of pharmaceuticals and intermediates for usage in the veterinary and human health.
Ajay Tandon
EXECUTIVE DIRECTOR, VEEDA CLINICAL RESEARCH PVT. LTD.
Veeda Clinical Research is an independent CRO which offers a fully integrated package to its clients.
Mohan Jain
DIRECTOR, NAPROD LIFE SCIENCES
Naprod Life Sciences provides life-saving cancer medications at affordable prices to patients around the world.
Bindi Chudgar
MANAGING DIRECTOR, LAMBDA THERAPEUTIC RESEARCH
Lambda discusses opportunities in India's domestic market and its recent expansion abroad through the acquisition of Novum.
Prashant Nagre
CEO, FERMENTA BIOTECH LTD.
Fermenta Biotech Ltd. (FBL) is one of the top three producers of Vitamin D3 API in the world, as well as a provider of immobilized enzymes and enzyme technologies.
Vijay Rai
CHAIRMAN AKOLA CHEMICALS
Akola Chemicals produces hydrolysed proteins for the agricultural, animal feed, food, nutraceutical and cosmetics industries.
Jagdeep Shah
DIRECTOR, CLINICARE
Clinicare brings globally acclaimed drug delivery and packing solutions to India's top drug companies through its network of partners.
Daara B. Patel
SECRETARY GENERAL, IDMA
The IDMA helps to guide India’s pharmaceutical industry along its rapid path of growth towards becoming the largest global supplier of safe and efficacious medicines.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
